DE602006017107D1 - Detektionsmittel und therapeutischer wirkstoff für hoch malignen brustkrebs - Google Patents

Detektionsmittel und therapeutischer wirkstoff für hoch malignen brustkrebs

Info

Publication number
DE602006017107D1
DE602006017107D1 DE602006017107T DE602006017107T DE602006017107D1 DE 602006017107 D1 DE602006017107 D1 DE 602006017107D1 DE 602006017107 T DE602006017107 T DE 602006017107T DE 602006017107 T DE602006017107 T DE 602006017107T DE 602006017107 D1 DE602006017107 D1 DE 602006017107D1
Authority
DE
Germany
Prior art keywords
malignes
detector
therapeutic agent
breast cancer
breast
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602006017107T
Other languages
English (en)
Inventor
Yasushi Nakamura
Hironao Yasuoka
Masahiko Tsujimoto
Rieko Goto
Zenzaburo Tozuka
Kunio Momiyama
Kennichi Kakudo
Tomonori Takami
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
JCL Bioassay Corp
Original Assignee
JCL Bioassay Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by JCL Bioassay Corp filed Critical JCL Bioassay Corp
Publication of DE602006017107D1 publication Critical patent/DE602006017107D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DE602006017107T 2005-12-14 2006-12-08 Detektionsmittel und therapeutischer wirkstoff für hoch malignen brustkrebs Active DE602006017107D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2005361030 2005-12-14
PCT/JP2006/325008 WO2007069709A1 (ja) 2005-12-14 2006-12-08 高悪性度乳癌の検出剤および治療剤

Publications (1)

Publication Number Publication Date
DE602006017107D1 true DE602006017107D1 (de) 2010-11-04

Family

ID=38163011

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602006017107T Active DE602006017107D1 (de) 2005-12-14 2006-12-08 Detektionsmittel und therapeutischer wirkstoff für hoch malignen brustkrebs

Country Status (6)

Country Link
US (2) US8030014B2 (de)
EP (1) EP1962094B1 (de)
JP (1) JP4157157B2 (de)
DE (1) DE602006017107D1 (de)
DK (1) DK1962094T3 (de)
WO (1) WO2007069709A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010055950A1 (ja) * 2008-11-17 2010-05-20 財団法人ヒューマンサイエンス振興財団 癌間質の構成因子に対して特異的結合能を有する物質と抗腫瘍性化合物との複合体による新規の癌ターゲティング治療
JP6324730B2 (ja) * 2014-01-15 2018-05-16 地方独立行政法人 大阪府立病院機構 リンパ節郭清により得られた組織片中のリンパ節判別方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3524644A1 (de) 1985-07-10 1987-01-15 Heyl Chem Pharm Undulin und dessen peptidfragmente, verfahren zu deren herstellung und ihre verwendung
US5185450A (en) * 1991-02-19 1993-02-09 University Of South Florida Tetrazolium compounds for cell viability assays
JP2004151003A (ja) 2002-10-31 2004-05-27 Hiroko Nogi Ｍｕｃ１およびケラチン１９の検査方法
WO2004097030A2 (en) 2003-04-28 2004-11-11 Bristol-Myers Squibb Company Prognostic breast cancer biomarkers

Also Published As

Publication number Publication date
US8030014B2 (en) 2011-10-04
EP1962094B1 (de) 2010-09-22
JPWO2007069709A1 (ja) 2009-05-28
WO2007069709A1 (ja) 2007-06-21
US20110111414A1 (en) 2011-05-12
EP1962094A4 (de) 2009-06-24
JP4157157B2 (ja) 2008-09-24
DK1962094T3 (da) 2011-01-10
US20100215648A1 (en) 2010-08-26
EP1962094A1 (de) 2008-08-27

Similar Documents

Publication Publication Date Title
EP1937280A4 (de) Zusammensetzungen und verfahren zur diagnose und therapie von bcl2-assoziierten tumoren
EP1967209A4 (de) Therapeutisches mittel gegen prostatakrebs
EP1869224A4 (de) Methylierungsmarker zur diagnose und behandlung von krebs
EP1872124A4 (de) Diagnosemarker für brustkrebsbehandlung und -progression sowie verfahren zur verwendung davon
DE602006013864D1 (de) Röntgen-ct-gerät
EP1937845A4 (de) Verfahren und zusammensetzungen auf mikro-rna-basis zur diagnose, prognose und behandlung von brustkrebs
BRPI0818320A2 (pt) composição para tratamento de câncer de próstata (pca)
GB0812867D0 (en) X-ray tomography inspection systems
FI20060449A (fi) Mammografiamenetelmä ja mammografialaite
EP2127671A4 (de) Therapeutisches krebsmittel
DK2121139T3 (da) Formulations for cancer treatment
DK1954834T3 (da) Brystcancermarkører
BRPI0911112A2 (pt) composições e métodos para o tratamento do câncer de mama
DE602005026450D1 (de) Röntgenröhre und röntgenquelle
DE602006013094D1 (de) Krebsmittel
EP1937816A4 (de) Marker zur krebsdiagnose und verwendung davon
PT2101731T (pt) Endoxifeno para utilização no tratamento de cancro
EP1937831A4 (de) Verwendung von n-myristoyltransferase auf nichttumorgewebe zur krebsdiagnose
BRPI0813364A2 (pt) Métodos de diagnóstico e tratamento de câncer.
SI1858929T1 (sl) Diagnoza raka prostate
EP1841467A4 (de) Kombinationskrebstherapie mit anti-psma-antikörpern
EP2115458A4 (de) Verfahren zur diagnose der gesundheitszustände bei ovarialkarzinom und des risikos von gesundheitszuständen bei ovarialkarzinom
EP2331711A4 (de) Verfahren zur diagnose von krebs und bestimmung der gesamt- sowie krankheitsfreien überlebenszeit von krebspatienten
BRPI0812932A2 (pt) Composições e métodos de tratar câncer
EP1870711A4 (de) Markerprotein zur verwendung bei der diagnose von bauchspeicheldrüsenkrebs

Legal Events

Date Code Title Description
R082 Change of representative

Ref document number: 1962094

Country of ref document: EP

Representative=s name: ABK PATENTANWAELTE, DE